Cantor Fitzgerald Maintains Overweight on BioCryst Pharma, Raises Price Target to $29

Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ: BCRX ) with a Overweight and raises the price target from $27 to $29.